We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Eisai Company Ltd (PK) | USOTC:ESALY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 61.51 | 61.51 | 61.86 | 0.00 | 01:00:00 |
From Jun 2021 to Jun 2024
By Colin Kellaher
Merck & Co. and Eisai Co. on Monday said the European Commission has approved the combination of the combination of Eisai's Lenvima and Merck's Keytruda in a pair of indications.
Merck, based in Kenilworth, N.J., and Tokyo-based Eisai said the approvals include the combination for the first-line treatment of adults with advanced renal cell carcinoma, the most common type of kidney cancer.
The companies said the combination is also now approved for adults with advanced or recurrent endometrial cancer who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who aren't candidates for curative surgery or radiation.
Eisai and Merck in March 2018 formed a collaboration to jointly develop, manufacture and commercialize Lenvima as monotherapy and in combination with Merck's blockbuster cancer drug Keytruda.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 29, 2021 07:13 ET (12:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Eisai (PK) Chart |
1 Month Eisai (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
